A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Trial details
- Registry ID
- NCT06111235
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as CG0070
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235 | CGON | Phase 3 | Active not recruiting | 2026-11Estimated |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCNCT06567743 | CGON | Phase 2 | Recruiting | 2027-03-31Estimated |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinNCT04452591 | CGON | Phase 3 | Active not recruiting | 2030-06-16Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |